Results 151 to 160 of about 3,685,138 (295)

Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma. [PDF]

Front Genet
Cui K, Zhu R, Li J.
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Chronic interferon signaling at baseline is associated with acquired resistance to immunotherapy in metastatic melanoma. [PDF]

Cell Rep Med
Egan D, Shum B, Fidan R, Kolch W, Brennan D, Lobon I, Turajlic S.   +6 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations. [PDF]

Nat Commun
Huang X, Cao X, Zheng L, Luo R, Fang Z, Liang Y, Zhu Y, Chen S, Zheng L, Xu Z, Li X, Liang G, Chen L.   +12 more
europepmc   +1 more source

Systemic Acquired Resistance [PDF]

HortScience, 1995
Scott Uknes, Bernard Vernooij, Shericca Williams, Danielle Chandler, Kay Lawton, Terrance Delaney, Leslie Friedrich, Kris Weymann, David Negrotto, Thomas Gaffney, Manuela Gut-Rella, Helmut Kessmann, Danny Alexander, Eric Ward, John Ryals   +14 more
openaire   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Taxanes Versus Pemetrexed After Osimertinib Resistance in EGFR-Mutated NSCLC: A Retrospective Cohort with Two-Model In Vitro Validation

Cancer Management and Research
Ning Yang,1,* Ning Wan,2,3,* Ya Guo,2,3 Lijuan Xiong,4 Xiting Chen,4 Dou Du,4 Bo Xie,1,4 Juan Zhou1,4 1Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, People’s Republic of China; 2Department of Clinical ...
Yang N, Wan N, Guo Y, Xiong L, Chen X, Du D, Xie B, Zhou J   +7 more
doaj  

Acquired resistance of cancer therapies: Mechanisms and perspectives. [PDF]

Chin Med J (Engl)
Wang M, Zhai X, Li J, Chen J, Gai X, Liu X, Liu Y, Zhou Q, Chen C.   +8 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source